Received May 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
We had a patient in our office that got his first dose of Shingrix December of 2022 and just got his second dose May of 2025; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of drug dose administration interval too long in a male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (got his first dose of Shingrix December of 2022). On an unknown date, the patient received the 2nd dose of Shingrix. In MAY-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: We had a patient in our office that got his first dose of Shingrix December of 2022 and just got his second dose May of 2025). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 14-MAY-2025 This case was reported by a consumer via interactive digital media. The reporter reported that they had a patient in our office that got his first dose of Shingrix December of 2022 and just got his second dose May of 2025, which was the clearly past the recommended 6 months. The patient received 2nd dose of Shingrix later than the recommended schedule, which led to lengthening of vaccination schedule. The reporter wanted to ask if the patient should start the series over and get a third dose or only the two doses or not.